Nexalin Technology receives U.S. patent for neurostimulation method
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St falls as tech losses, Middle East tensions deepen
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Micron to deliver 'another strong quarter', Goldman says
- Supermicro plans $7 billion financing to fund AI server orders
- UK's Ofcom requires tech firms to create crisis response plans
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
June 4, 2026 10:00 AM EDTNewly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalins proprietary position in non-invasive frequency-based deep-brain neurostimulation
Patent covers transcranial alternating current dynamic frequency stimulation methods for anxiety, depression and insomnia three large and underserved markets central to Nexalins HALO Clarity and NeuroCare strategies
HOUSTON, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (Nexalin or the Company), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the brain, today announced that the United States Patent and Trademark Office has issued... More
